Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options

Affiliations

¹ Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas2Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas.
² Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas3Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas.
³ Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas.

Saad A Khan et al. JAMA Oncol. 2016.

. 2016 Nov 1;2(11):1507-1508.

doi: 10.1001/jamaoncol.2016.2238.

¹ Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas2Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas.
² Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas3Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas.
³ Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas.

No abstract available

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

1. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–2017. - PMC - PubMed
1. February 11th, 2016; Available from: http://www.aarda.org/autoimmune-information/autoimmune-statistics.
1. Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer. 2009;100(5):822–828. - PMC - PubMed
1. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol. 2016;2(2):234–240. - PubMed